IceCure Medical regains Nasdaq compliance with minimum bid price rule

PR Newswire··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

IceCure Medical has regained compliance with Nasdaq's minimum bid price requirement. The company received written notice from Nasdaq on June 18, 2026, confirming that its ordinary shares maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from June 4 to June 17, 2026. Nasdaq now considers the bid price deficiency matter closed.

Impact on assets 1

Biotech & Genomic Medicine▲ · 1 stocks
Icecure Medical
ICCM
▲ PositiveRegulationrelevance

Regained Nasdaq compliance with minimum bid price rule, removing delisting risk.

© 2026 MarketIVNews